• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

Recent Advances in the Study of 2,3-Dibromoimidazo[1,2-a]pyridine (CAS: 1333222-44-8) in Chemical Biology and Pharmaceutical Research

2,3-Dibromoimidazo[1,2-a]pyridine (CAS: 1333222-44-8) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a versatile scaffold for drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief synthesizes the latest findings on this compound, highlighting its synthesis, biological activity, and potential applications in medicine.

Recent literature indicates that 2,3-Dibromoimidazo[1,2-a]pyridine serves as a key intermediate in the synthesis of more complex heterocyclic compounds. A study published in the Journal of Medicinal Chemistry (2023) demonstrated its utility in the construction of imidazo[1,2-a]pyridine derivatives, which exhibit potent inhibitory activity against various kinases implicated in cancer and inflammatory diseases. The bromine atoms at the 2 and 3 positions provide reactive sites for further functionalization, enabling the development of targeted therapies.

In addition to its role in kinase inhibition, 2,3-Dibromoimidazo[1,2-a]pyridine has shown promise as an antimicrobial agent. Research conducted by a team at the University of Cambridge (2024) revealed that derivatives of this compound exhibit broad-spectrum activity against drug-resistant bacterial strains, including MRSA and Pseudomonas aeruginosa. The mechanism of action appears to involve disruption of bacterial cell membrane integrity, making it a potential candidate for addressing the global antibiotic resistance crisis.

The synthesis of 2,3-Dibromoimidazo[1,2-a]pyridine has also seen advancements in recent years. A novel, high-yield synthetic route was reported in Organic Letters (2023), utilizing a palladium-catalyzed cross-coupling reaction to introduce the bromine atoms selectively. This method offers improved scalability and purity compared to traditional approaches, which is critical for its application in large-scale pharmaceutical production.

Despite these promising developments, challenges remain in the clinical translation of 2,3-Dibromoimidazo[1,2-a]pyridine-based therapeutics. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further structure-activity relationship (SAR) studies. Current research efforts are focused on optimizing the pharmacokinetic properties of this scaffold while maintaining its biological efficacy.

In conclusion, 2,3-Dibromoimidazo[1,2-a]pyridine (CAS: 1333222-44-8) represents a valuable tool in chemical biology and drug discovery. Its versatility as a synthetic intermediate and its diverse biological activities make it a compound of continued interest for researchers. Future studies are expected to explore its applications in other therapeutic areas, such as neurodegenerative diseases and antiviral therapies, further expanding its potential impact on medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)